ACADIA Pharmaceuticals Inc. $ACAD Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH reduced its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 58.0% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 47,094 shares of the biopharmaceutical company’s stock after selling 64,913 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in ACADIA Pharmaceuticals were worth $1,005,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. Marshall Wace LLP increased its stake in shares of ACADIA Pharmaceuticals by 496.2% during the second quarter. Marshall Wace LLP now owns 1,969,711 shares of the biopharmaceutical company’s stock worth $42,487,000 after acquiring an additional 1,639,315 shares during the period. Norges Bank purchased a new stake in ACADIA Pharmaceuticals in the 2nd quarter valued at approximately $31,679,000. Adage Capital Partners GP L.L.C. acquired a new position in ACADIA Pharmaceuticals during the 2nd quarter worth approximately $13,024,000. Arrowstreet Capital Limited Partnership acquired a new position in ACADIA Pharmaceuticals during the 2nd quarter worth approximately $7,257,000. Finally, Prudential Financial Inc. raised its stake in shares of ACADIA Pharmaceuticals by 93.3% during the 2nd quarter. Prudential Financial Inc. now owns 685,477 shares of the biopharmaceutical company’s stock worth $14,786,000 after buying an additional 330,876 shares in the last quarter. Hedge funds and other institutional investors own 96.71% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ACAD. Citigroup upped their price objective on ACADIA Pharmaceuticals from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a research note on Monday, December 29th. UBS Group raised their price objective on shares of ACADIA Pharmaceuticals from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Piper Sandler set a $37.00 price objective on shares of ACADIA Pharmaceuticals in a report on Tuesday, December 16th. Finally, JPMorgan Chase & Co. dropped their target price on shares of ACADIA Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating for the company in a report on Monday, November 17th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $31.16.

ACADIA Pharmaceuticals Price Performance

Shares of ACAD opened at $25.13 on Friday. ACADIA Pharmaceuticals Inc. has a 1-year low of $13.40 and a 1-year high of $28.35. The stock has a market cap of $4.25 billion, a price-to-earnings ratio of 16.21, a price-to-earnings-growth ratio of 6.22 and a beta of 0.68. The firm has a 50 day simple moving average of $26.49 and a 200-day simple moving average of $24.40.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.28. The firm had revenue of $278.63 million for the quarter, compared to analyst estimates of $276.52 million. ACADIA Pharmaceuticals had a return on equity of 14.61% and a net margin of 24.94%.ACADIA Pharmaceuticals’s revenue was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.20 EPS. On average, equities analysts expect that ACADIA Pharmaceuticals Inc. will post 0.7 earnings per share for the current fiscal year.

Insider Activity at ACADIA Pharmaceuticals

In related news, EVP Mark C. Schneyer sold 10,262 shares of ACADIA Pharmaceuticals stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $23.69, for a total transaction of $243,106.78. Following the completion of the sale, the executive vice president owned 53,338 shares in the company, valued at approximately $1,263,577.22. This trade represents a 16.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider James Kihara sold 4,084 shares of the company’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $23.69, for a total transaction of $96,749.96. Following the completion of the transaction, the insider owned 25,058 shares in the company, valued at approximately $593,624.02. This trade represents a 14.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 44,346 shares of company stock valued at $1,010,957 over the last quarter. Insiders own 26.50% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.